<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084473</url>
  </required_header>
  <id_info>
    <org_study_id>GADEX</org_study_id>
    <nct_id>NCT01084473</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine on Gastric Emptying and Gastrointestinal Transit</brief_title>
  <acronym>GADEX</acronym>
  <official_title>Effect of Dexmedetomidine Infusion on Gastric Emptying and Gastrointestinal Transit in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Turku</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turku</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to determine the effect of dexmedetomidine infusion on gastric
      emptying and oro-caecal transit time in healthy volunteers, judged by measuring plasma
      paracetamol concentrations after paracetamol ingestion and pulmonary hydrogen measurement
      technique after lactulose ingestion. The effects of dexmedetomidine will be compared to the
      effects of morphine and placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effect of dexmedetomidine on gastric emptying and oro-caecal transit time</measure>
    <time_frame>10, 15, 20, 30, 40, 45, 50, 60, 70, 75, 80, 90, 105, 120, 135, 150, 165, 180, 210 and 240 min</time_frame>
    <description>5 ml venous blood samples will be collected immediately prior to administration of paracetamol (baseline) and thereafter at 10, 20, 30, 40, 50, 60, 70, 80, 90, 105, 120, 135, 150, 165, 180, 210 and 240 min into EDTA tubes for determination of paracetamol plasma concentrations. End-expiratory breath samples will be obtained immediately prior to administration of lactulose (baseline) and thereafter at 15, 30, 45, 60, 75, 90, 105 and 120 min.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Gastric Emptying</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The study subjects will be given a saline infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9 % NaCl will be infused.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Normal cognitive function and fluent skills in the Finnish language in order to be
             able to give informed consent and communicate with the study personnel

          -  Age ≥ 18 years.

          -  Male gender.

          -  Weight ≥ 60 kg.

          -  Written informed consent from the subject.

        Exclusion Criteria:

          -  Previous history of intolerance to the study drugs or related compounds and additives.

          -  Concomitant drug therapy of any kind except ibuprofen in the 14 days prior to the
             study days.

          -  Existing or recent significant disease.

          -  History of haematological, endocrine, metabolic or gastrointestinal disease.

          -  History of asthma or any kind of drug allergy.

          -  Previous or present alcoholism, drug abuse, psychological or other emotional problems
             that are likely to invalidate informed consent, or limit the ability of the subject to
             comply with the protocol requirements.

          -  A positive test result for urine toxicology.

          -  A &quot;yes&quot; answer to any of the questions in a modified Finnish version of the Abuse
             Questions

          -  Donation of blood within six weeks prior to and during the study.

          -  Special diet or lifestyle factors which would compromise the conditions of the study
             or the interpretation of the results.

          -  BMI &gt; 30 kg / m2.

          -  Participation in any other clinical study involving investigational or marketed drug
             products concomitantly or within one month prior to the entry into this study.

          -  Smoking during one month before the start of the study or during the study period.

          -  Clinically significant abnormal findings in physical examination, ECG or laboratory
             screening [routine haematology (haemoglobin, haematocrit, red blood cell count, white
             blood cell count, platelets), renal function tests (creatinine, urea) and liver
             function tests (bilirubin)].
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timo Iirola, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University, Turku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anaesthesiology, Intensive Care, Emergency Care and Pain Medicine, Turku University and Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2010</study_first_submitted>
  <study_first_submitted_qc>March 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2010</study_first_posted>
  <last_update_submitted>June 3, 2010</last_update_submitted>
  <last_update_submitted_qc>June 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Timo Iirola</name_title>
    <organization>Turku University Hospital and Turku University</organization>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>gastric emptying</keyword>
  <keyword>oro-cecal transit time</keyword>
  <keyword>Sedation in intensive care</keyword>
  <keyword>Gastrointestinal effects of sedation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Lactulose</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

